Replies to post #35730 on RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

I agree with you on the conference call--it is too premature to host one. On the other hand, they gave us no indication of what they plan to do moving forward, and that is in stark contrast to previous news releases following study results. Take, for instance, the last sections of the press release following the second RD study completion results:

"...We are now extending our preclinical studies to determine whether AMPAKINE molecules can help the breathing problems in prematurely born babies and in adults with sleep apnea. This has been, and continues to be, an extremely productive collaboration with Cortex that is resulting in the translation of our basic scientific discoveries to clinical applications.”

Cortex plans to continue the development of AMPAKINE compounds in opioid-induced RD. An intravenous dosage form of CX717 is being finalized, and a follow-on compound, CX1942, a water soluble pro-drug of a novel AMPAKINE compound with improved potency over CX717, will shortly enter preclinical development for RD. Additionally, a novel AMPAKINE molecule, CX1739, is currently in Phase I clinical trials and is targeted to begin Phase II clinical trials for ADHD in Q2 2009.

Perhaps shareholders aren't the only ones clueless as to where we go from here, or if they have a good strategy moving forward, they were too thoughtless to share. I'm with Patco on where we stand as shareholders.